Items where authors include "Lipton, A."

Article

Gineyts, E., Bonnet, N., Bertholon, C. et al. (17 more authors) (2018) The C-terminal intact forms of periostin (iPTN) are surrogate markers for osteolytic lesions in experimental breast cancer bone metastasis. Calcified Tissue International, 103 (5). pp. 567-580. ISSN 0171-967X

Lipton, A., Smith, M.R., Fizazi, K. et al. (8 more authors) (2016) Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients With Advanced Cancer and Bone Metastases Treated With Bone Antiresorptive Agents. Clinical Cancer Research, 22 (23). pp. 5713-5721. ISSN 1078-0432

Lipton, A., Fizazi, K., Stopeck, A.T. et al. (12 more authors) (2016) Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. EUROPEAN JOURNAL OF CANCER, 53. pp. 75-83. ISSN 0959-8049

Coleman, R.E. orcid.org/0000-0002-4275-1043, Lipton, A., Costa, L. et al. (9 more authors) (2013) Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials. Journal of Bone Oncology, 2 (2). pp. 70-76. ISSN 2212-1366

Coleman, R.E. orcid.org/0000-0002-4275-1043, Lipton, A., Roodman, G.D. et al. (11 more authors) (2010) Metastasis and bone loss: Advancing treatment and prevention. Cancer Treatment Reviews, 36 (8). pp. 615-620. ISSN 0305-7372

Major, P.P., Cook, R.J., Lipton, A. et al. (3 more authors) (2009) Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer, 9. 272.